## FUTURE PLANS

For further details of our future plans, please see the section headed "Business — Our Strategies" in this Document.

## USE OF [REDACTED]

We estimate that the aggregate net **[REDACTED]** to our Company from the **[REDACTED]** will be approximately HK$**[REDACTED]** million, after deducting **[REDACTED]** fees and estimated expenses in connection with the **[REDACTED]** payable by us and based on an **[REDACTED]** of HK$**[REDACTED]** per H Share.

We currently intend to apply such net **[REDACTED]** from the **[REDACTED]** for the following purposes (among which an aggregate of approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used for the clinical development and commercialization of our Core Products), subject to changes in light of our evolving business needs and changing market conditions:

(i) approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) to fund the further promotion of clinical research relating to our existing pipeline products (among which approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used for the clinical development of our Core Products). Particularly, our Core Products and key product are still at phase I or phase II of drug clinical trials, for instance, our Core Products have commenced phase II clinical trials in PRC in the third quarter of 2025, and are further expected to commence phase II clinical trials in U.S. in 2026, and our key product, namely XJN026 is also expected to enter into phase I clinical trial in 2026. The R&D expenses for later stages of clinical development are expected to be higher than that of pre-clinical and phase I clinical trial R&D expenses, specifically, our Core Products and key product will still have to carry out multiple phases of drug clinical trials, including phase I clinical trials, phase II clinical trials and phase III clinical trials. Due to the cash intensive nature of clinical development, we therefore plan to allocate approximately HK$**[REDACTED]** million to fund the clinical development of our pipeline products as follows:

a. approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used to fund the ongoing clinical development and regulatory submissions of our Core Product DHMP.

i. approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used for funding clinical development of preoperative sedation in children aged 2 to 6 years old in PRC until the NDA are approved, of which:

— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used to fund the phase III clinical trial in PRC which is expected to commence in Q4 2026 and complete in Q4 2027; and

— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used to fund the regulatory submission expenses of different stages of the clinical development in PRC.

ii. approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used for funding clinical development of preoperative sedation in adults in PRC until the NDA are approved, of which:

— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used to fund the phase II clinical trial in PRC which commenced in Q1 2026 and is expected to complete in Q4 2026;

— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used to fund the phase III clinical trial in PRC which is expected to commence in Q1 2027 and complete in Q4 2027; and

— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used to fund the regulatory submission expenses of different stages of the clinical development in PRC.

iii. approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used for funding clinical development of preoperative sedation in adults in U.S. until the NDA are approved, of which:

— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used to fund the phase I clinical trial in U.S. which is expected to commence in Q4 2026 and complete in Q3 2027;

— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the phase II clinical trial in U.S. which is expected to commence in Q4 2027 and complete in Q4 2027;
— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the phase III clinical trial in U.S. which is expected to commence in Q1 2029 and complete in Q1 2030; and
— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the regulatory submission expenses of different stages of the clinical development in U.S.

b. approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]% of the net [**REDACTED**]) will be used to fund the ongoing clinical development and regulatory submissions of our Core Product XJN010.

i. approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]% of the net [**REDACTED**]) will be used for funding clinical development of our Core Product XJN010 in PRC until the NDA are approved, of which:

— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the phase III clinical trial in PRC which is expected to commence in Q4 2026 and complete in Q4 2027; and
— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the regulatory submission expenses of different stages of the clinical development in PRC.

ii. approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]% of the net [**REDACTED**]) will be used for funding clinical development of our Core Product XJN010 in U.S. until the NDA are approved, of which:

— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the phase II clinical trial in U.S. which is expected to commence in Q3 2026 and complete in Q2 2027;
— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the phase III clinical trial in U.S. which is expected to commence in Q4 2028 and complete in Q4 2029; and
— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the regulatory submission expenses of different stages of the clinical development in U.S.

c. approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]% of the net [**REDACTED**]) will be used to fund the ongoing clinical development and regulatory submissions of our key product XJN026.

i. approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]% of the net [**REDACTED**]) is expected to be used to fund the phase I clinical trial in PRC which is expected to commence in Q2 2026 and complete in Q4 2026.

ii. approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]% of the net [**REDACTED**]) will be used for funding clinical development of XJN026 in U.S., of which:

— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the U.S. registration agent fee;
— approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to fund the phase I clinical trial in U.S. which is expected to commence in [Q2 2027] and complete in [Q1 2028].

d. approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]% of the net [**REDACTED**]) will be used to fund our other products' preclinical studies and the preparation for IND submission and Phase I clinical trial, of which:

i. approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used for the preclinical studies and the preparation for IND submission of XJN1102;

ii. approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used for the Phase I clinical trials of XJN1102.

(ii) approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) (among which approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used for the commercialization of our Core Products) primarily to fund the expansion of our production capacity and secondarily to support the commercialization of pipeline products upon regulatory approval and sales authorization, which includes:

a. approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used for the microneedle formulation industrial base, of which:

— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used to fund the leasing costs of the leased premises, the nature of which is operating lease, for the microneedle formulation industrial base and is expected to be fully utilized by the year end of 2027;
— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used for renovation and maintenance of the microneedle formulation industrial base and is expected to be fully utilized by the year end of 2027; and
— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used for the procurement of manufacturing equipment to be used in the microneedle formulation industrial base and is expected to be fully utilized by the year end of 2026.

b. approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used for the nasal inhalation formulation industrial base, of which:

— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used to fund the leasing costs of the leased premises, the nature of which is operating lease, for nasal inhalation formulation industrial base and is expected to be fully utilized by the year end of 2027;
— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used for renovation and maintenance of the nasal inhalation formulation industrial base and is expected to be fully utilized by the year end of 2027; and
— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used for the procurement of manufacturing equipment to be used in the nasal inhalation formulation industrial base and is expected to be fully utilized by the year end of 2026.

c. approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**% of the net **[REDACTED]**) will be used for the commercialization of our Core Products upon regulatory approval, which includes:

i. approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used for the commercialisation of DHMP, of which:

— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used to establish and maintain one in-house marketing team, including the recruitment of around 8 to 15 marketing personnel with pharmaceutical business development experiences and/or business management experiences and an expected average annual remuneration in the range of approximately RMB0.2 million to RMB0.4 million. Their primary functions include, among others, formulating marketing and product pricing strategies, developing and maintaining sales channels, and leading and managing marketing campaigns and events;
— approximately HK$**[REDACTED]** million (or approximately **[REDACTED]**%), is expected to be used for the development and maintenance of approximately 50 to 60 sales channels, including but not limited to (a) the engagement of external contract sales organizations (CSOs) to advance commercialization through their distribution network, particularly those with pre-existing hospitals distribution network and track record, (b) direct distribution through local distributors, and (c) collaboration with local pharmacies under direct-to-patient (DTP) model; and

- approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used for marketing activities, including but not limited to (a) hosting or sponsoring academic conferences, (b) collaborating with key opinion leaders (KOLs), (c) preparing marketing materials such as patients education materials, product manuals and prescription guidelines, at our products salesterminals, and (d) other marketing activities in different platforms, such as participating in industry conferences and marketing campaigns through our social media, online and other media platforms.

ii. approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used for the commercialisation of XJN010, of which:

- approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used to establish and maintain one in-house marketing team, including the recruitment of around 8 to 15 marketing personnel with pharmaceutical business development experiences and/or business management experiences and an expected average annual remuneration in the range of approximately RMB0.2 million to RMB0.4 million. Their primary functions include, among others, formulating marketing and product pricing strategies, developing and maintaining sales channels, and leading and managing marketing campaigns and events;
- approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used for the development and maintenance of approximately 50 to 60 sales channels, including but not limited to (a) the engagement of external contract sales organizations (CSOs) to advance commercialization through their distribution network, particularly those with pre-existing hospitals distribution network and track record, (b) direct distribution through local distributors, and (c) collaboration with local pharmacies under direct-to-patient (DTP) model; and
- approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]%), is expected to be used for marketing activities, including but not limited to (a) hosting or sponsoring academic conferences, (b) collaborating with key opinion leaders (KOLs), (c) preparing marketing materials such as patients education materials, product manuals and prescription guidelines, at our products sales terminals, and (d) other marketing activities in different platforms, such as participating in industry conferences and marketing campaigns through our social media, online and other media platforms.

(iii) approximately HK$[**REDACTED**] million (or approximately [**REDACTED**]% of the net [**REDACTED**]) will be used for our working capital and other general corporate purposes.

If the [**REDACTED**] are exercised in full, the net [**REDACTED**] of the [**REDACTED**] would increase to approximately HK$[**REDACTED**] million (based on the [**REDACTED**] of HK$[**REDACTED**] per H Share). We intend to apply the additional net [**REDACTED**] to the above uses in the proportion set out above.

The above allocation of the net [**REDACTED**] from the [**REDACTED**] will be adjusted on a pro rata basis in the event that the [**REDACTED**] is fixed at a higher or lower level compared to the mid-point of the indicative [**REDACTED**] range stated in this Document.

To the extent that our net [**REDACTED**] are not sufficient to fund the purposes set out above, we intend to fund the balance through a variety of means, including cash generated from operations, bank loans and other borrowings. If the net [**REDACTED**] of the [**REDACTED**] are not immediately applied to the above purposes, to the extent permitted by relevant law and regulations, we will only deposit such funds into short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions (as defined under the Securities and Futures Ordinance or applicable laws and regulations in other jurisdictions).

In the event of any material change in our use of net [**REDACTED**] of the [**REDACTED**] from the purposes described above or in our allocation of the net [**REDACTED**] among the purposes described above, a formal announcement will be made.